If enacted, this legislation will significantly affect health insurance policies regarding breast cancer diagnosis and testing. By mandating that no cost-sharing be imposed on diagnostic or supplemental breast examinations, the bill seeks to encourage individuals to seek timely medical advice and intervention, potentially leading to earlier detection of breast cancer. The changes are expected to apply to plan years starting on January 1, 2026, allowing insurers time to adjust their policies and requirements.
Summary
House Bill 3037, known as the Access to Breast Cancer Diagnosis Act of 2025, aims to amend the Public Health Service Act by prohibiting group health plans and health insurance issuers from imposing cost-sharing requirements for diagnostic and supplemental breast examinations. The bill intends to remove financial barriers for individuals seeking these potentially life-saving screenings, thus promoting greater access to necessary medical evaluations for breast cancer.
Contention
Notably, the bill allows for certain exceptions, such as permitting plans to impose prior authorization and other utilization controls. This aspect may be a point of contention among stakeholders as some may view it as a necessary measure to ensure appropriate use of resources, while others might argue it still introduces potential barriers to access. Furthermore, the bill clarifies that states can enact more favorable protections, which could lead to variations in coverage depending on state-specific laws.
Additional_points
This legislation reflects a growing recognition of the importance of preventive healthcare in improving health outcomes, particularly for women at risk of breast cancer. Supporters assert that eliminating cost-sharing will remove obstacles to care, while opponents may raise concerns about the possible ramifications for insurance premiums and the overall healthcare funding structure.
Requiring that certain health insurance plans impose a no-cost sharing requirement for a diagnostic or supplemental breast cancer examination for breast cancer imposed on an insured.